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AbstrACt
Objective To report and evaluate a new Vision Impairment 
Screening Assessment (VISA) tool intended for use by the 
stroke team to improve identification of visual impairment 
in stroke survivors.
Design Prospective case cohort comparative study.
setting Stroke units at two secondary care hospitals and 
one tertiary centre.
Participants 116 stroke survivors were screened, 62 by 
naïve and 54 by non-naïve screeners.
Main outcome measures Both the VISA screening tool 
and the comprehensive specialist vision assessment 
measured case history, visual acuity, eye alignment, eye 
movements, visual field and visual inattention.
results Full completion of VISA tool and specialist vision 
assessment was achieved for 89 stroke survivors. Missing 
data for one or more sections typically related to patient’s 
inability to complete the assessment. Sensitivity and 
specificity of the VISA screening tool were 90.24% and 
85.29%, respectively; the positive and negative predictive 
values were 93.67% and 78.36%, respectively. Overall 
agreement was significant; k=0.736. Lowest agreement 
was found for screening of eye movement and visual 
inattention deficits.
Conclusions This early validation of the VISA screening 
tool shows promise in improving detection accuracy for 
clinicians involved in stroke care who are not specialists in 
vision problems and lack formal eye training, with potential 
to lead to more prompt referral with fewer false positives 
and negatives. Pilot validation indicates acceptability of 
the VISA tool for screening of visual impairment in stroke 
survivors. Sensitivity and specificity were high indicating 
the potential accuracy of the VISA tool for screening 
purposes. Results of this study have guided the revision of 
the VISA screening tool ahead of full clinical validation.
bACkgrOunD  
Visual impairment following stroke is 
common and estimated to affect two-thirds 
of all stroke survivors.1 There is currently 
no standardised protocol for screening 
or referral and, as a result of poor/absent 
screening, a considerable proportion of 
patients who have visual problems go unrec-
ognised, thus receiving no advice or manage-
ment.2 There are various visual treatment 
options that can have a beneficial effect on 
vision and to general rehabilitation.3–5 Visual 
impairment can have a substantial impact on 
quality of life including loss of confidence, 
impaired mobility, inability to judge distances 
and increased risk of falls.3 There is a known 
link between poor vision, quality of life and 
depression in older persons.4 6 For these 
reasons, it is important that patients with 
visual impairment are identified by the stroke 
multidisciplinary team (MDT) and appro-
priate referral made for specialist vision assess-
ment. It is equally important that the effects 
of visual impairment on functional ability 
are established and information is provided 
regarding the use of residual vision to facili-
tate general rehabilitation. These issues have 
been recognised as research priorities in the 
James Lind Alliance sight loss prioritisation 
process, in which screening and assessment 
of stroke survivors for visual problems is listed 
as a top 10 priority for research.7 
The overall aim of this study was to develop 
and evaluate a Vision Impairment Screening 
Assessment (VISA) tool using simple estab-
lished assessments of visual function coupled 
with detailed instructions. Our objectives were 
to test the VISA screen against a reference of a 
specialist vision assessment to determine sensi-
tivity, specificity, predictive values and inter-rater 
agreement of results between the VISA screen 
and specialist vision assessments. A final objec-
tive was to evaluate user views on the accept-
ability of use of the VISA screening tool.
MethODs
Development
The VISA screening tool was developed 
following consultation with an expert 
panel consisting of: stroke-specialist clinical 
strengths and limitations of this study
 ► Iterative development process for the screening tool.
 ► Prospective clinical pilot validation process.
 ► Comparison made between naïve and non-naïve 
screeners.
 ► Acceptability of the screening assessment to stroke 
survivors was not captured.
 ► The duration of the screening assessment was not 
captured.
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orthoptists, stroke research orthoptists, stroke survivors 
with visual impairment, stroke-specialist occupational 
therapists and neuro-ophthalmologists. The panel consid-
ered results of recent stroke/vision research studies in 
which multiple measures of visual function were made.2 8 
They identified the consistent vision measures across the 
common visual impairments occurring following stroke—
those of impaired central vision, eye movement, visual 
field and visual inattention (the vision modality of spatial 
neglect).
Stroke survivors provided specific input on potential 
burden of these assessments to individuals, particularly 
when undertaken in the early acute stage post-stroke 
onset. Following this panel discussion, a draft screening 
tool was circulated along with detailed instructions 
compiled for each of the screening assessments, which 
comprised a screen of visual symptoms and observed signs, 
visual acuity, eye alignment and movements, visual field 
boundaries and visual inattention. An iterative process 
was followed in which the panel provided written feed-
back on the first and subsequent drafts of the screening 
tool. Feedback from both clinicians and stroke survivors 
guided the revision of the symptom history section to 
reduce the number of questions being asked and refine 
the question wording to remove potential ambiguity. 
Feedback specifically from clinicians also guided the revi-
sion of the self-guided instructions to provide more steps 
and detail plus to remove potential ambiguity.
The final pilot version of the VISA tool contained 
the same five sections as the original draft, consisting 
of a case history section in which visual symptoms and 
observed signs are documented, a visual acuity section to 
screen central vision at near and distance using logMAR 
and N-series letters, an ocular alignment and movement 
section to screen the presence/absence of strabismus 
(eye position) and eye movement problems, a visual field 
section to screen for peripheral field of vision by a guided 
confrontation method, and a visual perception section 
to screen for visual inattention/neglect using a triad of 
line bisection, cancellation task and clock drawing assess-
ments. The VISA tool provides detailed instructions 
regarding correct use of the assessments required for 
screening. This self-directed design with the incorpora-
tion of detailed instructions as part of the tool was devel-
oped on the basis that many stroke clinicians do not have 
any formal eye training and may not have access to such 
training. Thus, the aim was to provide in-built instruc-
tions in lieu of formal training.
Pilot validation
A prospective case cohort comparative design was used 
for the pilot validation clinical study. Individuals were 
suitable for inclusion if they were 18 years of age or 
older, had clinical diagnosis of stroke as defined by 
the WHO,9 had the ability to agree to vision screening 
using verbal or non-verbal indications of agreement, 
did not have severe cognitive impairment preventing 
screening and did not decline vision screening. Our 
inclusion criteria were intended to be pragmatic and 
inclusive of as many stroke survivors as possible. The 
clinical study was undertaken in accordance with the 
Tenets of Helsinki with the National Health Service 
(NHS) research ethical approval.
For the purpose of this study, vision screening was 
undertaken with the VISA screening tool and screening 
was defined as the assessment of stroke survivors for the 
presence of reduced visual function against preset abnor-
mality criteria. Specialist visual assessment was defined as 
the vision assessment undertaken by eye-trained clinicians 
(orthoptists and ophthalmologists) in which detection of 
visual impairment was coupled with formal diagnosis of 
the type of visual condition present.
Recruitment took place across three hospitals in which 
an orthoptist was a member of the core acute stroke unit 
MDT (as per national guidelines: Royal College of Physi-
cians Intercollegiate Stroke Guidelines and British and 
Irish Orthoptic Society extended guidelines for stroke 
practice).10 11
Each stroke survivor underwent two vision assess-
ments: the routine orthoptic specialist vision assess-
ment (n=5 orthoptists/ophthalmologists) and the 
VISA screening assessment. The VISA screen was 
completed by medical students and orthoptists. 
Medical students (n=2) were chosen as screeners to 
represent completely naïve individuals in conducting 
vision screening assessments. Orthoptists (n=4) were 
Table 1 Calculations of sensitivity, specificity and 
predictive values
Positive
True positive, that is, visual 
impairment present and 
referred 74
False negative, that is, visual 
impairment present but not 
referred 8
Negative
False positive, that is, visual 
impairment not present but 
referred 5
True negative, that is, visual 
impairment not present and 
not referred 29
Output
Sensitivity (true positive/true 
positive+false negative)
90.24%
(95% CI 81.68% to 95.69%)
Specificity (true negative/
false positive+true negative)
85.29%
(95% CI 68.94% to 95.05%)
Positive predictive 
value (true positive/false 
positive+true positive)
93.67%
(95% CI 86.78% to 97.09%)
Negative predictive 
value (true negative/false 
negative+true negative)
78.38%
(95% CI 64.91% to 87.66%)
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also chosen as screeners in this pilot stage of valida-
tion to serve as a quality check of the screening tool’s 
ability to accurately assess various aspects of visual 
impairment.
Routine specialist vision assessment comprised detailed 
diagnostic assessments of case history, visual acuity, ocular 
alignment and movement, visual field and visual percep-
tion. This assessment was undertaken within 24 hours 
(typically the same day) of the VISA screen—to minimise 
effect of potential recovery.
The order of the VISA screening and specialist 
vision assessments varied to avoid the effects of fatigue 
and bias towards either the screen or vision assess-
ments. The screener and orthoptist were blinded to 
each other’s assessments to prevent bias of assessment. 
The within-assessment order of testing varied for the 
specialist assessment. However, the order of testing 
within the VISA screen followed a set order of (1) case 
history, (2) visual acuity, (3) eye position, (4) visual 
field and (5) visual inattention assessments.
statistical methodology and sample size
Results were taken in numerical format from the referral 
forms completed by both the screener and the orthoptist. 
The specialist vision assessment was taken as the refer-
ence standard.
The primary outcome measure was presence 
or absence of visual impairment (defined as low 
vision <0.2, visual field loss, eye movement abnor-
mality, visual perceptual abnormality) and recorded 
as a binary measure: yes/no for presence/absence of 
visual impairment. The primary outcome measure was 
evaluated by kappa values assessing chance-eliminated 
agreement between the VISA screening and specialist 
vision assessment results.
Secondary outcome measures were the calculation 
of sensitivity, specificity and predictive values. Level of 
sensitivity was estimated as the proportion of patients 
with visual impairment who are correctly identified 
by the screener, and the corresponding 95% CI was 
calculated. Level of specificity was estimated as the 
proportion of patients without visual impairment who 
are correctly identified by the screener, and the corre-
sponding 95% CI. Further, we calculated the positive 
and negative predictive values for the VISA screen.
As this was a pilot validation study, we sought to 
include a minimum sample size of 100 subjects. This 
sample size is typically used for diagnostic accuracy 
studies, which we considered appropriate even though 
this was a study of screening detection rather than 
diagnostic accuracy.12
Figure 1 Flow diagram of participant outcome for screening and full assessment.
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Process evaluation
Process evaluation for acceptability of the VISA tool 
during the clinical study was through a combination of 
feedback sheets and one-to-one interviews with screeners. 
Feedback sheets could be returned at any time during the 
study to report any issues with testing alongside obtaining 
clinician views based on their use of the VISA tool. Feed-
back sheets asked the following:
1. Are the instructions for the various tests clear?
2. Which instructions should be amended?
3. What additional instruction information/rewording 
do you suggest?
4. Which instructions require less information?
5. Are any tests not useful or difficult to do? (Specify.)
6. Should any other tests be added in?
7. How long does it take you to do the screen?
8. Other comments?
These questions were also asked during individual 
interviews. Interviews were conducted by the lead author 
(FJR).
Interviews and feedback sheets were transcribed 
verbatim and all identifying features removed. Qualita-
tive data analysis was undertaken as an ongoing iterative 
process. All transcripts were systematically coded manu-
ally. A thematic approach to analysis of the qualitative 
data was adopted. Transcripts were coded by sentence 
or section and the code descriptors were derived directly 
from the text. A thematic approach to analysis of the qual-
itative data was adopted. Codes were grouped for similar 
content and these groups defined the key emerging 
themes. A modified grounded theory approach was 
undertaken in which themes were revised iteratively as 
further interviews and analysis progressed.
results
Completion rate
One hundred and sixteen patients with stroke received 
both a VISA screening assessment and a reference vision 
assessment over 4 months (December 2015 to March 
2016). Two medical students conducted 62 of the VISA 
screens and 54 were screened by a team of four orthoptists. 
Independent specialist vision assessment was conducted 
by a team of four orthoptists and one ophthalmologist.
The VISA screen was fully completed by 89 patients, 
with the remaining 28 missing one or more elements 
(near vision n=4, distance vision n=6, convergence n=3, 
visual fields n=9, visual inattention n=28). The specialist 
vision assessment was fully completed by 77 patients, with 
the remaining 40 missing one or more elements (near 
vision n=3, distance vision n=9, convergence n=18, visual 
fields n=9, visual inattention n=23). Reasons for missing 
data were captured and typically related to patient’s 
inability to complete sections of vision assessments because 
of impaired cognitive ability or fatigue. All patients were 
included even if there were missing data—missing data 
did not automatically result in failure for that section, 
thereby requiring referral. Reasons behind the failure to 
complete sections were always taken into consideration. 
referral agreement
The agreement of whether to make a referral to specialist 
eye services based on the results of the VISA screening 
tool versus those from specialist vision assessment had a 
kappa value of 0.736 (95% CI 0.602 to 0.870).
In this pilot evaluation of the VISA screening tool, sensi-
tivity of 90.24% and specificity of 85.29% were found. The 
positive and negative predictive values were 93.67% and 
Table 2 Summary of agreement between the VISA screen and specialist vision assessment for referral to specialist eye 
services and individual components
Element of testing Agreement False negative False positive Kappa value (95% CI)
Referral 103 8 5 0.736 (0.602 to 0.870)
Near visual acuity 93 10 7 0.682 (0.543 to 0.820)
Distance visual acuity 94 8 3 0.785 (0.665 to 0.904)
Ocular alignment 112 4 0 0.585 (0.221 to 0.949)
Ocular motility 89 21 6 0.120 (−0.071 to 0.311)
Visual fields 94 3 8 0.741 (0.599 to 0.884)
Visual inattention 67 1 16 0.361 (0.144 to 0.578)
VISA, Vision Impairment Screening Assessment.
Table 3 Summary of agreement between the VISA screening tool and specialist vision assessment for referral to specialist 
eye services when used by a naïve versus non-naïve screener
Screener Agreement False negative False positive Kappa value (95% CI)
Medical student
n=62
51 7 4 0.617 (0.415 to 0.820)
Independent orthoptist
n=54
52 1 1 0.899 (0.761 to 1.000)
VISA, Vision Impairment Screening Assessment.
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78.36%, respectively. These calculations are outlined in 
table 1.
Agreement was found for 103 participants (29 had 
no visual impairment, 74 required referral because of 
failed screening), outlined in figure 1. The VISA screen 
produced eight false negative and five false positive 
results. Of the false negative results, three had ocular 
motility problems, three had reduced distance vision, 
one had reduced near vision and one did not have visual 
fields tested during screening. For false positive results, 
two with visual inattention, two with visual field loss and 
one with both visual inattention and visual field loss were 
detected by screening and found not to be present by the 
specialist vision assessment.
test component agreement
The agreement for the individual components between 
the VISA screen and specialist vision assessments is 
outlined in table 2. The highest levels of agreement 
were produced for distance visual acuity (0.785) 
and visual fields (0.741). The lowest levels of agree-
ment were produced for ocular motility (0.120) and 
visual inattention (0.361). Low agreement for ocular 
motility related to high false negatives where 21 cases 
(three with multiple conditions) were not detected—
these comprised: nine defects of vertical movement 
(including four age-related restrictions, one IVth cranial 
nerve palsy and one V pattern), eight cases of nystagmus 
(including four end-point nystagmus), five restrictions 
of horizontal eye movements and four cases of reduced 
convergence. The low agreement with visual inattention 
related to false positive referrals because of failure of 
the patient to complete this section due to impaired 
cognitive ability or fatigue—rather than true presence 
of visual inattention.
naïve versus non-naïve screeners
The agreement on whether to make a referral to specialist 
eye services based on results of the VISA screening tool 
versus those from specialist vision assessment was stronger 
when made by a non-naïve screener (table 3). A higher 
rate of false positives and false negatives was found when 
the screener was naïve to vision testing (11 false referrals 
for naïve vs 2 for non-naïve screeners). The agreement 
on whether to make a referral to specialist eye services 
between the VISA screening tool and a specialist vision 
assessment had a kappa value of 0.736 (95% CI 0.602 to 
0.870).
When used by a naïve screener the VISA screen has 
a sensitivity of 82.93% and specificity of 80.95%. When 
used by non-naïve screeners the VISA screen has a sensi-
tivity of 97.56% and specificity of 92.31%.
Process evaluation
Information from feedback sheets and detailed notes 
from interviews were compiled and grouped for type of 
feedback. Group themes included instruction feedback, 
section feedback and referral feedback.
Instruction feedback
Screeners asked for brief instruction reminders at the 
top of VISA screening assessments, for example, posi-
tion test chart at 3 m from the patient, cover each eye in 
turn, and so on. This served to act as a quick reminder for 
the correct procedure for that particular section of the 
screening tool. Clarifications were requested for the main 
instruction training section such that potential ambiguity 
was removed.
Section feedback
In the first version, each screening section was coupled to 
the detailed assessment instructions. Screeners requested 
that all detailed instructions be merged into one training 
‘manual’ section with the screening assessments sepa-
rate. As screeners became more familiar with the tool, 
they used the VISA screens on their own and kept the 
detailed instructions elsewhere (mainly for reference) 
which meant there was less paperwork to be carried to 
the bedside assessment.
Referral feedback
Most feedback concerned patients who were borderline 
on whether to refer for specialist vision assessment or not. 
For example, where the patient had borderline visual 
acuity responses—perhaps because glasses were not avail-
able—but all other visual function assessments passed the 
VISA screen. In other cases, the patient lacked sufficient 
cognitive or communication abilities rendering some 
VISA screens ‘unsure’ or incomplete. Detailed referral 
guidelines were compiled to guide the referral process 
with minimum guidance being to repeat the VISA screen 
1–2 days later for borderline cases. This aimed to reduce 
the levels of false referrals.
DisCussiOn
In this study, we present the VISA screening tool which 
encompasses screening of key visual functions affected 
by stroke; namely central vision, peripheral visual field, 
eye position/movements and visual attention, along-
side ocular history. Overall, referral had sensitivity and 
specificity of about 90% and 80%, respectively, positive 
and negative predictive values of about 94% and 78%, 
respectively, with agreement between VISA screening and 
comprehensive specialist assessment of above kappa 0.7. 
Agreement was lowest for eye movement screening and 
visual inattention whereas all other individual sections 
showed agreement of above kappa 0.5. Low agreement 
in these sections related to high false positive referrals 
where VISA screen indicated a fail for ocular motility 
or visual inattention. The specialist vision assessment 
detected ocular motility changes which were classed as 
‘normal’ physiological eye movement patterns such as V 
pattern and end-point nystagmus, and which alone would 
not have required referral. The detection of these physio-
logical eye movement patterns was regarded as a positive 
finding within the eye movement section indicating that 
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the ocular motility section had proved to be sensitive to 
these less obvious eye movement problems. However, this 
section requires close monitoring in further studies to 
refine related training and referral guidelines. False posi-
tive referrals for visual inattention occurred where the 
patient failed to complete the section because of fatigue 
or cognitive impairment. The incomplete results were 
interpreted as borderline fail by screeners. Visual inat-
tention was the last section to be completed in the VISA 
screen so, as a result, was likely to be most susceptible to 
the effects of fatigue and impaired cognition. Guidance 
on completing the VISA screen was therefore amended 
such that the more interactive components of the VISA 
screen (ie, visual field and visual inattention sections) 
were advised to be completed first in cases where cogni-
tion or fatigue could impact on screen complete; plus a 
repeat second screen was advised where indicated.
Process evaluation aided further refinement of the 
VISA screening tool and, in particular, training elements 
and referral guidance to add quick tips and reminders, 
and to remove ambiguity. Vision screening of stroke survi-
vors by orthoptists using validated assessments has been 
shown to provide accurate identification of visual impair-
ment and is easily undertaken on the stroke unit with 
further follow-up arranged in eye clinics as required.13 
Such orthoptic input has been reported to help prevent 
misdiagnosis, provide quick access to treatment of visual 
problems and improve response to general rehabilita-
tion.4 14 Orthoptists are a member of the core acute stroke 
MDT.10 Despite consistent findings that inclusion of vision 
services within the MDT is highly beneficial, such visual 
assessment is not common and services are inconsistent 
throughout the UK. One survey showed that 45% of stroke 
services provided no formal vision assessment for patients 
with stroke.15 A further survey of practice identified that 
only 7% of stroke units had a policy relating to vision 
assessment and management.16 Both surveys showed lack 
of standardisation for vision assessment and treatment for 
stroke survivors. The National Stroke Strategy argues that 
vision and visual perceptual difficulties are components 
requiring multifaceted stroke-specific rehabilitation and 
support.17 The Royal College of Physicians recommend 
that every patient with stroke should have a practical 
assessment of vision and examination of the visual field.10
Problems exist with referral accuracy from the MDT 
where there is suspected visual difficulty. It is reported 
that where referral by the MDT was based on the iden-
tification of ocular signs only, there was reduced sensi-
tivity (42%) and specificity (52%).3 Referral accuracy 
improved when visual symptoms were taken into account. 
Concerns were raised regarding potential failure to refer 
those patients unable to report their visual symptoms due 
to communication and cognitive deficits.3 Inconsistencies 
between identification of ocular signs on assessment by 
the MDT and final ocular diagnosis have also been docu-
mented in an audit of stroke referrals for vision assess-
ment.18 Fifty-six per cent of visual diagnoses made prior 
to formal eye assessment were incorrect with amended 
diagnoses being made following visual assessment by 
the orthoptic/ophthalmic team.18 Our VISA screen at 
this early pilot stage appears to increase the accuracy of 
screening by increasing the ability to detect ocular signs 
separate from reporting of vision symptoms.
In each of the above studies, the MDT used a screening 
form on which they specified whether they noted any 
obvious visual signs such as nystagmus, strabismus or 
ptosis and whether the patient complained of visual 
symptoms such as double vision or reading difficulty. 
They did not, however, undertake any measurement of 
visual function. A further study evaluated Cardiff cards 
as a screening measure to identify low levels of vision.19 
A comparative study of qualitative methods of visual field 
assessment reported the difficulty in screening for visual 
field impairment in acute stages of stroke follow-up.20 
However, the authors recognised that confrontation is 
widely regarded as the most viable screening option for 
bedside visual field assessment.19 Visual inattention is 
the most common visual perceptual disorder and there 
are various screening assessments in use for its detection 
but which do not extend to other facets of visual impair-
ment.21 In each of these studies, individual assessments of 
one aspect of visual function are considered. However, an 
overall visual screening assessment for stroke survivors is 
currently not available for use by MDTs in the absence of 
assessment by eye care professionals.21
limitations
The VISA screening tool was used by a combination of 
medial students and orthoptists while specialist vision 
assessment was provided by a team of orthoptists and 
ophthalmologists. Arguably, results wold be more mean-
ingful if all VISA screens were completed by staff naïve to 
any vision assessment. Because this was a pilot validation 
study, we chose to include VISA screens from both medical 
students with no vision assessment experience and ortho-
ptists who were experienced in vision assessment. Medical 
students represented completely naïve individuals in 
conducting vision screening assessments. However, 
orthoptists were chosen as screeners in this pilot stage 
of validation to serve as a quality check of the screening 
tool’s ability to accurately assess various aspects of visual 
impairment. Our process evaluation for acceptability of 
the VISA screen involved feedback and interviewers with 
screeners only. We acknowledge this limitation and an 
important next step is to obtain views of stroke survivors 
on the acceptability of the VISA screen and its perceived 
value to them. A further limitation is that the VISA screen 
was not timed consistently for duration. Completion of 
the VISA screen was approximately 10 min in the small 
number that could be assessed but this cannot be taken as 
a representative screen duration. The screening duration 
is an important consideration when adding to busy acute 
stroke services and will be captured fully in the next stage 
of validation.
Our next stage of development is a full clinical valida-
tion of the VISA tool where all screening assessments are 
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completed by naïve screeners versus reference compre-
hensive vision assessment.
COnClusiOns
This early validation of the VISA screening tool shows 
promise in improving detection accuracy for clinicians 
involved in stroke care who are not specialists in vision 
problems and lack formal eye training, with potential to 
lead to more prompt referral with fewer false positives 
and negatives. Clinicians reported acceptability of the 
VISA screening tool for use in screening for presence of 
vision problems in stroke survivors. Referral sensitivity 
of 90% and specificity of 80% were found for the VISA 
screening with strong inter-rater agreement for referral 
between VISA screening and specialist vision assessments.
The benefits are that the VISA screening tool may 
support increased speed of access to appropriate treat-
ment of visual impairment and potential to preserve and 
make best use of remaining visual function for patients. 
Identification of visual impairment and implementation 
of early interventions and compensatory options have 
impact to overall rehabilitation, quality of life and activi-
ties of daily living with potential cost savings to the NHS by 
enhancing rehabilitation and supporting early discharge. 
Establishment of an effective vision screening tool is likely 
to be highly transferable to other vulnerable groups in 
other hospital inpatient areas, residential care settings or 
community MDT assessments.
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